- $1.89bn
- $4.28bn
- $2.78bn
- 67
- 71
- 58
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.59 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.63 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.15% | ||
| Return on Equity | -51.61% | ||
| Operating Margin | -70.46% | ||
Financial Summary
| Year End 29th Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,661.67 | 1,698.55 | 3,266 | 2,997.8 | 2,782.9 | 2,703.91 | 2,817.07 | 39.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +839.49 | -11.94 | -29.53 | -90.23 | n/a | n/a | +38.86 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Directors
- Kenneth Buechler NEC (67)
- Douglas Bryant CEO (63)
- Randall Steward CFO (66)
- Robert Bujarski COO (52)
- Michelle Hodges SVP (61)
- William Ferenczy SVP (65)
- Karen Gibson SVP (59)
- Werner Kroll SVP (64)
- Tamara Ranalli SVP (48)
- Edward Russell SVP (53)
- Edward Michael IND (64)
- Mary Polan IND (77)
- Ann Rhoads IND (56)
- Matthew Strobeck IND (48)
- Kenneth Widder IND
- Joseph Wilkins IND (59)
- Last Annual
- December 29th, 2024
- Last Interim
- December 29th, 2024
- Incorporated
- December 17th, 2021
- Public Since
- February 1st, 1991
- No. of Shareholders
- 84
- No. of Employees
- 6,600
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 67,454,614
- Address
- 9975 Summers Ridge Road, SAN DIEGO, 92121
- Web
- https://www.quidelortho.com/
- Phone
- +1 8585521100
- Contact
- Juliet Cunningham
- Auditors
- Ernst & Young LLP
Latest News for QDEL
Upcoming Events for QDEL
Q1 2025 QuidelOrtho Corp Earnings Release
Q1 2025 QuidelOrtho Corp Earnings Call
QuidelOrtho Corp Annual Shareholders Meeting
QuidelOrtho Corp Annual Shareholders Meeting
Q2 2025 QuidelOrtho Corp Earnings Release
Similar to QDEL
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 22:49 UTC, shares in Quidelortho are trading at $28.09. This share price information is delayed by 15 minutes.
Shares in Quidelortho last closed at $28.09 and the price had moved by -29.23% over the past 365 days. In terms of relative price strength the Quidelortho share price has underperformed the S&P500 Index by -34.67% over the past year.
The overall consensus recommendation for Quidelortho is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreQuidelortho does not currently pay a dividend.
Quidelortho does not currently pay a dividend.
Quidelortho does not currently pay a dividend.
To buy shares in Quidelortho you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $28.09, shares in Quidelortho had a market capitalisation of $1.89bn.
Here are the trading details for Quidelortho:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: QDEL
Based on an overall assessment of its quality, value and momentum Quidelortho is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Quidelortho is $53.29. That is 89.71% above the last closing price of $28.09.
Analysts covering Quidelortho currently have a consensus Earnings Per Share (EPS) forecast of $2.36 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quidelortho. Over the past six months, its share price has underperformed the S&P500 Index by -23.46%.
As of the last closing price of $28.09, shares in Quidelortho were trading -29.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Quidelortho PE ratio based on its reported earnings over the past 12 months is 10.59. The shares last closed at $28.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Quidelortho's management team is headed by:
- Kenneth Buechler - NEC
- Douglas Bryant - CEO
- Randall Steward - CFO
- Robert Bujarski - COO
- Michelle Hodges - SVP
- William Ferenczy - SVP
- Karen Gibson - SVP
- Werner Kroll - SVP
- Tamara Ranalli - SVP
- Edward Russell - SVP
- Edward Michael - IND
- Mary Polan - IND
- Ann Rhoads - IND
- Matthew Strobeck - IND
- Kenneth Widder - IND
- Joseph Wilkins - IND